𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of comorbidity on post-treatment quality of life scores in patients with head and neck squamous cell carcinoma

✍ Scribed by Christine G. Gourin; Brian J. Boyce; Creighton C. Vaught; Lori M. Burkhead; Robert H. Podolsky

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
106 KB
Volume
119
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objectives/Hypothesis:

To determine the effect of comorbidity on 1‐year post‐treatment quality of life (QOL) in patients with head and neck squamous cell cancer (HNSCC).

Methods:

One hundred twenty‐five previously untreated HNSCC patients participated in longitudinal QOL analysis over a 28‐month period. The University of Washington QOL questionnaire, Performance Status Scale, and Karnofsky score were used to measure QOL. Generalized estimating equations were used to analyze the effects of patient variables and their interaction with time.

Results:

The majority of patients (74%) had advanced stage (III/IV) disease; advanced comorbidity was present in 30%. Early tumor, node, metastases (TNM) stage was associated with significantly greater decreases in 1‐year chewing and swallowing scores (P < .0001) than advanced stage disease. Nonoperative treatment was associated with significantly poorer 1‐year shoulder and taste scores for early TNM stage, in contrast to advanced stage disease (P = .01). Comorbidity alone did not affect any of the QOL indices, but showed an interaction with treatment and primary site for appearance and chewing scores, respectively. Patients with high‐grade comorbidity had poorer 1‐year survival (80% for early stage disease, 55% for advanced stage disease) than patients with low‐grade comorbidity (100% for early stage disease, 69% for advanced stage disease).

Conclusions:

These data suggest that patient perception of disability, rather than the extent and severity of disease, influences the majority of head and neck disease‐specific QOL indices. Analysis of the effects of comorbidity on post‐treatment QOL is limited by increased mortality in patients with advanced comorbidity. Laryngoscope, 2009

📜 SIMILAR VOLUMES

Efficacy of neck treatment in patients w
Efficacy of neck treatment in patients with head and neck squamous cell carcinoma
✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the

Impact of comorbidity on outcome of youn
Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma
✍ Bhuvanesh Singh; Mahesh Bhaya; Marc Zimbler; Jordan Stern; J. Thomas Roland; Ric 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 3 views

Background. Comorbid conditions have a significant impact on the actuarial survival of patients with head and neck cancer. However, no studies have evaluated the impact of comorbidity on tumor-and treatment-specific outcomes. This study was performed to evaluate the impact of comorbidity, graded by

Factors associated with nonparticipation
Factors associated with nonparticipation in one-year quality-of-life assessment in patients with head and neck squamous cell carcinoma
✍ Christine G. Gourin; Kavon C. Kaboli; Brian J. Boyce; Lori M. Burkhead 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

## Abstract ## Objectives/Hypothesis: To identify factors associated with nonparticipation in long‐term quality‐of‐life (QOL) analysis in head and neck squamous cell cancer (HNSCC) patients. ## Study Design: Restrospective analysis of prospectively collected data. ## Methods: Two hundred sixty

Prevalence and incidence of acute and ch
Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck
✍ Sarah H. Landis; Iman A. El-Hariry; Myrthe P. P. van Herk-Sukel; Pieter van den 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 1 views

## Abstract ## Background Limited data exist on the burden of comorbidity among patients with squamous cell head and neck cancer (SCCHN) before and during cancer treatment. ## Methods The precancer prevalence and incidence rates of 8 comorbid conditions were estimated among a population‐based co